Form 4 Tracker
Sandra Calvin

SVP, CHIEF ACCOUNTING OFFICER · 2 filings · Latest: Apr 14, 2026

Travere Therapeutics, Inc.
TickerOwnerRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Filing
TVTX
Sandra CalvinSVP, CHIEF ACCOUNTING OFFICERApr 14, 2026
Sale
$41.0721,977$902.6K42,353
TVTX
Sandra CalvinSVP, CHIEF ACCOUNTING OFFICERApr 14, 2026
Option Exercise
$16.0515,250$244.8K64,330
TVTX
SANDRA CALVINApr 14, 2026
Proposed Sale
$41.0721,977$902.6K
TVTX
Sandra CalvinFeb 3, 2026
Proposed Sale
$32.124,333$139.2K
TVTX
Sandra CalvinSVP, CHIEF ACCOUNTING OFFICERFeb 3, 2026
Sale
$32.124,333$139.2K49,080
TVTX
SANDRA CALVINDec 24, 2025
Proposed Sale
$40.007,402$296.1K
TVTX
SANDRA CALVINDec 15, 2025
Proposed Sale
$36.002,910$104.8K
TVTX
SANDRA CALVINNov 4, 2025
Proposed Sale
$36.0067,115$2.4M
TVTX
SANDRA CALVINFeb 11, 2025
Proposed Sale
$25.0054,244$1.4M
TVTX
Sandra CalvinFeb 3, 2025
Proposed Sale
$20.123,348$67.4K
TVTX
SANDRA CALVINDec 26, 2024
Proposed Sale
$17.2215,000$258.3K
TVTX
Calvin SandraNov 25, 2024
Proposed Sale
$18.3012,090$221.3K
TVTX
Calvin SandraSep 11, 2024
Proposed Sale
$14.8015,000$222.0K